Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Kevin Lamote (Gent, Belgium), Kevin Lamote, Matthijs Vynck, Joris Van Cleemput, Olivier Thas, Kristiaan Nackaerts, Jan P. Van Meerbeeck. Volatile organic compounds increase the likelihood of detecting malignant pleural mesothelioma. Eur Respir J 2015; 46: Suppl. 59, 5002

Member's Comments

No comment yet.

Related content which might interest you: Volatile organic compounds as an early diagnostic tool for malignant pleural mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014 A breath test for malignant mesothelioma using an electronic nose Source: Eur Respir J 2012; 40: 448-454 Year: 2012 Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013 Drug repurposing in malignant pleural mesothelioma: a breath of fresh air? Source: Eur Respir Rev, 27 (147) 170098; 10.1183/16000617.0098-2017 Year: 2018 Comparison of multiple serum and pleural fluid biomarkers for the diagnosis of Malignant Pleural Mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Exhaled breath analysis allows exclusive screening for malignant pleural mesothelioma. Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Breath analysis allows to predict treatment response in malignant pleural mesothelioma patients. Source: Virtual Congress 2021 – Novel insights into the diagnosis, mechanism and treatment of malignant pleural disease Year: 2021 Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Detection of EpCAM-positive microparticles in pleural fluid: A new approach for the diagnosis of the tumoral origin of pleural effusions Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Volume quantification of malignant pleural mesothelioma Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Role of Dr-70 immunoassay in suspected malignant pleural effusion Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Exhaled breath to screen for malignant pleural mesothelioma: a validation study Source: Eur Respir J, 50 (6) 1700919; 10.1183/13993003.00919-2017 Year: 2017 Volatile organic compounds in exhaled breath of patients with COPD ± lung cancer and their correlation with FEV1-values Source: International Congress 2014 – The assessment of comorbidities Year: 2014 Biological markers of successful pleurodesis for malignant pleural effusion Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016 Volatile organic compounds in COPD: Is hexanal an inflammation biomarker? Source: International Congress 2016 – The future of lung function is beginning now Year: 2016 Ideal volume sampling in the diagnosis of malignant pleural effusions. Just how much is really enough? Source: Annual Congress 2013 –Progress in bronchoscopy and pathology techniques for diagnosis of thoracic malignancies Year: 2013 Differences in volatile organic compounds (VOC) determined in exhaled breath in two populations of lung cancer (LC): With and without COPD Source: Annual Congress 2013 –New methods for diagnostic workup of lung cancer Year: 2013 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Chemical characterization of exhaled breath to discriminate patients with malignant pleural mesothelioma from subjects with similar professional asbestos exposure Source: Annual Congress 2010 - Clinical diagnosis and management of malignant pleural effusions Year: 2010